[{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Symbiosis Pharmaceutical Services \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Symbiosis Pharmaceutical Services \/ AstraZeneca"}]

Find Clinical Drug Pipeline Developments & Deals by Symbiosis Pharmaceutical Services

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply.

                          Product Name : AZD1222

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 22, 2020

                          Lead Product(s) : ChAdOx1 nCoV-19

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank